Condition

Early-Stage Breast Cancer

ClinicalTrials.gov condition label

Clinical trials15
Recruiting5
Common interventions20
Lead sponsors shown12

Clinical trials

15 shown
1-Week Versus 3-Week PBINCT07832279 · 2026-10-01
RECRUITING
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerNCT07796880 · 2026-09-14
RECRUITING
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant TreatmentNCT07366112 · 2026-04-20
RECRUITING
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerNCT06970912 · 2025-08-01
RECRUITING
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast CancerNCT05906407 · 2019-04-19
RECRUITING
PBI for Low-risk Breast CancerNCT07814365 · 2026-09-13
WITHDRAWN
Cryoablation Versus Lumpectomy in Early-Stage Breast CancerNCT07483996 · 2026-04-01
NOT_YET_RECRUITING
Testing of the Cancer Thriving and Surviving Breast Cancer ProgramNCT03651921 · 2017-12-12
COMPLETED
Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer PatientsNCT02982148 · 2015-05-01
UNKNOWN
Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast CancerNCT00636441 · 2008-04-01
TERMINATED
Survey of Optical Values of the Breast Using Radiation-Free Pressure-Free Optical ScanningNCT00671385 · 2008-04-01
UNKNOWN
Patient Centered Randomized Controlled TrialNCT00233077 · 2006-10-01
COMPLETED
A Couples Approach to Enhance Breast Cancer SurvivorshipNCT00665899 · 2004-07-01
COMPLETED
Proton Therapy for Early Stage Breast CancerNCT00614172 · 2004-02-01
COMPLETED
Tangential Radiation Therapy Without Axillary Dissection in Breast CancerNCT00165243 · 1998-09-01
COMPLETED

Common interventions

Trial status mix

COMPLETED5
RECRUITING5
UNKNOWN2
NOT_YET_RECRUITING1
TERMINATED1
WITHDRAWN1

Phase mix

NA6
PHASE25
PHASE31
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.